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0022-2836© 2010 Published by ElsevierMelanocortin-4 receptor (MC4R) has an important regulatory role in energy
homeostasis and food intake. Peptide agonists of the MC4R are character-
ized by the conserved sequence His6-Phe7-Arg8-Trp9, which is crucial for
their interaction with the receptor. This investigation utilized the covalent
attachment approach to identify receptor residues in close proximity to the
bound ligand [Nle4,D-Phe7]melanocyte-stimulating hormone (NDP-MSH),
thereby differentiating between residues directly involved in ligand binding
and those mutations that compromise ligand binding by inducing
conformational changes in the receptor. Also, recent X-ray structures of
G-protein-coupled receptors were utilized to refine a model of human
MC4R in the active state (R⁎), which was used to generate a better
understanding of the binding mode of the ligand NDP-MSH at the atomic
level.
The mutation of residues in the human MC4R—such as Leu106 of
extracellular loop 1, and Asp122, Ile125, and Asp126 of transmembrane
(TM) helix 3, His264 (TM6), and Met292 (TM7)—to Cys residues produced
definitive indications of proximity to the side chains of residues in the core
region of the peptide ligand. Of particular interest was the contact between
D-Phe7 on the ligand and Ile125 of TM3 on the MC4R. Additionally, Met292
(TM7) equivalent to Lys(7.45) (Ballesteros numbering scheme) involved in
covalently attaching retinal in rhodopsin is shown to be in close proximity
to Trp9.
For the first time, the interactions between the terminal regions of NDP-
MSH and the receptor are described. The amino-terminus appears to be
adjacent to a series of hydrophilic residues with novel interactions at Cys196
(TM5) and Asp189 (extracellular loop 2). These interactions are reminiscent
of sequential ligand binding exhibited by the β2-adrenergic receptor, with
the former interaction being equivalent to the known interaction involving
Ser204 of the β2-adrenergic receptor.© 2010 Published by Elsevier Ltd.Open access under CC BY license. Keywords: comparative model; cysteine cross-linking; G-protein-coupled
receptor (GPCR); melanocortin-4 receptor (MC4R); [Nle4,D-Phe7]melano-
cyte-stimulating hormone (NDP-MSH)Edited by I. B. Hollandiochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
.ac.uk; John.Findlay@nuim.ie.
perial DrugDiscovery Center, Imperial College London, South KensingtonCampus,
ocortin-4 receptor; NDP-MSH, [Nle4,D-Phe7]melanocyte-stimulating hormone; TM,
receptor; GPCR, G-protein-coupled receptor; MSH, melanocyte-stimulating
, β-(2-naphthyl)-D-alanine; ECL, extracellular loop; hMC4R, human MC4R; PDB,
RE, cyclic AMP response element; CuP, copper 1,10-phenanthroline; MC1R,
bility density function.
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434 Melanocortin-4 Receptor/NDP-MSH InteractionsIntroductionMelanocortin receptors (MCRs) belong to the G-
protein-coupled receptor (GPCR) family A and, upon
stimulation, elevate cyclic adenosine-3′,5′-monopho-
sphate (cAMP) levels. The melanocortin-4 receptor
(MC4R) is one of five members of the MCR family
and is located primarily in the brain, where it has an
important role in energy homeostasis and regulation
of food intake. The MC4R is, therefore, a potential
therapeutic target in both anorexia and obesity.1–3
The agonists of the receptor, the melanocyte-stimu-
lating hormones (MSHs) (or α-MSH, β-MSH, and
γ-MSH), are derived from proopiomelanocortin by
proteolysis, and all have a conserved core tetrapep-
tide sequence His6-Phe7-Arg8-Trp9,
4–8 which is the
minimal sequence required for activation of the
receptor.9,10
An important secondary structural element found
in peptide hormones that stimulate GPCRs is a
reverse turn, or β-turn, where the direction of the
peptide chain is reversed at the fourth residue.4,11 The
distance between the first residue and the fourth
residue is defined as less than 7 Å, and an α-helical
secondary structure is not formed. A hydrogen bond
between the carbonyl group of the first residue and
the amide of the third peptide bond stabilizes β-turns
within the peptide chain.12 Several NMR structures of
a peptide agonist based on α-MSH-derived
analogues13–15 and melanotan II (MTII)13,16–21 have
been released. Due to the size and flexibility of the
structures, a general consensus for the orientation of
most of the amino acids is still being debated.22
However, there is general agreement that a β-turn-
like structure forms around core residues 6–9, but
even here, there are variations. The NMR studies of
Cho et al. on [Nle4,D-Phe7]melanocyte-stimulating
hormone (NDP-MSH) suggested that the central
residues forming the turn conformation are the His6-
D-Phe7 pair.
20 In contrast, Hogan et al. studied cyclic
decapeptides with the consensus tetrapeptide se-
quence His6-D-Phe7-Arg8-Trp9 locked in a type II′ β-
turn, with the heart of the turn being D-Phe7-Arg8.23
Alanine scanning of the tetrapeptide demonstrated
the functional consequence of modifying each
residue, and evidence has revealed that amino acid
substitution within this tetrapeptide sequence
results in a dramatic decrease in affinity for the
receptor. In contrast, replacement of the L-Phe
residue for D-Phe at position 7 of α-MSH (NDP-
MSH) potentiated the effect of the agonist.7,24 The
core tetrapeptide sequence has been modified
further into a cyclic compound known as MTII
(see Supplementary Material). Enlarging the ring
structure of MTII by substituting D-Phe for β-(2-
naphthyl)-D-alanine (D-Nal), which is a bulkier
amino acid, resulted in the production of the first
high-affinity antagonist SHU911925 (see Supple-
mentary Material). Truncation studies with α-MSH
suggested that terminal residues 1–3, 5, 10, and 12
played a role in potency, with the remainder having
no significant role in potency or affinity.26,27Furthermore, NDP-MSH residues 1–3, 5, and 13
have also been shown to be important in receptor
response.28
Mutagenesis studies6,23,29–39 and computer
modeling13 have predicted key residues contained
within the MC4R that are responsible for interacting
with agonist and antagonist ligands. Two types of
interactions have been proposed: an ionic interac-
tion between the positively charged Arg8 of the core
tetrapeptide and one or more acidic residues on the
receptor in transmembrane (TM) 2 (Glu100) and
TM3 (Asp122 and Asp126), and hydrophobic con-
tacts between the side chains of D-Phe7 and Trp9 on
the ligand and the hydrophobic side chains on TM4
(Phe184 and Tyr187), TM6 (Phe261, Phe262, His264,
and Phe267), and TM7 (Phe284).34,35 Mutations at
residues Asp122 and Asp126 (TM3) of the receptor
resulted in a large decrease in affinity for the agonist
(containing Arg8), but not for the antagonist (with
norleucine Nle8 substituted for Arg8). This sug-
gested a direct ionic interaction between Arg8 and
Asp122(3.25) and/or Asp126.35,37 Recent mutagen-
esis studies have focused on the binding pocket of
the peptide agonists α-MSH,40 γ-MSH,41 and N-D-
Nal(2′)7-adrenocorticotropic hormone(1–17)44 and
on the binding pocket of nonpeptide agonists such
as tetrahydroisoquinolone.45 However, many muta-
tions in the MC4R reduce the affinity for an agonist
that may not directly interact with the ligand, but
actually vary the conformation of the receptor with a
consequent change in the fine structure of the
binding site. Residues proposed to control receptor
conformation include Leu106 of extracellular loop
(ECL) 1 and Ile125(3.28) (TM3).23,37,42,43
The aim of this work is to identify molecular
interactions that occupy the binding pocket for the
peptide agonist of the MC4R by covalently attaching
cysteine peptide analogues of NDP-MSH to native
Cys residues on the receptor through thiol chemis-
try. Contacts involving the core tetrapeptide of
NDP-MSH are mapped when designated amino
acids within the human MC4R (hMC4R) are
substituted with a Cys residue and are shown to
covalently cross-link to Cys-containing peptides
within the tetrapeptide agonist sequence.
In an effort to deliver a more meaningful analysis,
we performed our cross-linking work in conjunction
with molecular modeling studies to provide a more
detailed examination of potential binding site
interactions. For many years, comparative modeling
of class A GPCRs was based on inactive R-state
(bovine rhodopsin) crystal structures, with an
ongoing challenge being the development of R⁎
active-state models. Several reports have indicated
that GPCR activation is accompanied by rigid-
domain motion of the intracellular portion of TM6
relative to TM346,47 and by counterclockwise rota-
tions of TM648 and TM349 from an extracellular
viewpoint. The crystal structure of opsin, solved in
2008, indicated that TM6 is tilted outwards by 6–7 Å
at the intracellular end, while TM5 is closer to TM6
when compared with the R-state structures [Protein
Data Bank (PDB) code 3CAP; 2.9 Å].50 More
435Melanocortin-4 Receptor/NDP-MSH Interactionsrecently, Scheerer et al. published a crystal structure
of the active GPCR opsin complexed with a C-
terminal peptide derived from the Gα subunit of
transducin GαCT(340–350)K341L (PDB code 3DQB;
3.2 Å), whose binding was further facilitated by a
restructured TM7–helix 8 kink.51 In this study, we
utilized these recently elucidated crystal structures
to generate R⁎-state models of the MC4R from
which a complex with NDP-MSH was developed in
a ligand-based modeling approach. The model was
utilized to examine the proposed interactions and
the role of the various mutations studied here and
reported earlier in the literature. In the process, we
attempted to define a preferred structure of the
bound ligand, most specifically the position of the
putative β-turn.Results
MC4R R⁎ model validation and analysis
Structural models of the hMC4R R⁎ state were
obtained as described in Materials and Methods
using the known 2.9–3.2 Å resolution structures of
the homologous class A GPCR opsin.50,51 The
validity of the developed hMC4R R⁎ models was
examined using a number of tools. The best model,
based on the 3DQB template with sequence align-
ment as depicted by Chai et al., had only one
stereochemical outlier (namely, Ser109 of ECL1) and
was hence deemed stereochemically satisfactory.29
Additionally, the model had an initial ERRAT52
score of 71.386, which is greater than the cutoff at 50.
After minimization of the model in MOE,53 a score
of 91.167, which is comparable to 89.058 scored by
the crystal structure and is indicative of a good ratio
of nonbonded interactions, was obtained.
An outline of the developed MC4R model
showing the seven TM regions and the two proline
kinks present at Pro260 (TM6) and Pro299 (TM7) is
presented in Fig. 1. The N-terminus, C-terminus,
and loops were modeled from the opsin template
with subsequent loop refinement. Notably, the
highly conserved ECL1 of the MCRs, containing
the acidic Asp-x-Asp motif, interacts with the N-
terminus and TM2. MCRs lack the characteristic
long ECL2 loop of class A GPCRs at the entrance of
the ligand binding pocket, which may allow greater
access to the binding pocket.54 In the opsin crystal
structure (PDB code 3DQB), GαCT(340–350)K341L
binds to an intracellular site opened by an outward
tilt of TM6, a pairing of TM5 and TM6, and a
restructured TM7–helix 8 kink.51 A number of
interactions with TM3, TM5, and TM6 of MC4R
involving GαCT and our developed MC4R model
were observed. First, His222 at the end of TM5
comes into contact with Ile340 and Glu342 of GαCT.
From TM3, Thr150 and Arg147 of the conserved
DRY motif form hydrogen bonds with Lys345 and
Asp346 of GαCT, respectively, while Lys242 of TM6
hydrogen bonds with Phe350 of GαCT.MC4R R⁎ model: Analysis of conserved motifs
Next, we examined the roles of conserved motifs
in both the opsin crystal structure and the MC4R R⁎
model that are postulated to have a role in
activation. In our static hMC4R model, the
Asp146-Arg147 interaction of the DRY motif is
broken, with Asp146 forming a hydrogen bond
with Arg165 at the start of TM4 (at 2.69 Å between
the closest heavy atoms), while Arg147 hydrogen
bonds with Ile143 (2.82 Å) and Ile151 (2.82 Å) of TM3
(Fig. 1). In both Ops⁎ and Ops⁎-GαCT structures,
the hydroxyl group of Tyr223 from TM5 replaces the
carboxyl group of Glu134 in its interaction with
Arg135 of ERY (2.89 Å), with the Arg side chain then
swinging into the center of the GαCT binding pocket
to form the floor of the pocket. In our hMC4Rmodel,
the equivalent Tyr212 of TM5 is in close proximity to
Arg147 (4.76 Å) and forms hydrogen bonds with
Leu140 (2.55 Å) of TM3, and Met208 (2.95 Å) and
Phe216 (2.81 Å) of TM5.
The highly conserved aspargine (N) of the NPxxY
motif in TM7 has been postulated to act as an on/off
switch by adopting two different conformations in
the inactive and active states.55 In the inactive state,
the Asn(7.49) side chain is orientated towards TM6,
either via a water molecule in rhodopsin56 or
through an interaction with the Thr(6.43)/Asp
(6.44) motif in the glycoprotein hormone receptor
family.55 Upon receptor activation, Asn(7.49) is
proposed to adopt the trans conformation to interact
with Asp(2.50) of the (N/S)LxxxD motif in TM2.
However, in the opsin crystal structures, Asn302
(Asn(7.49) of the NPxxY motif) in TM7 forms a
hydrogen-bond interaction with neighboring
Tyr306. This interaction is broken in our hMC4R
model, with Asp298 (DPxxY motif) forming inter-
actions with nearby Asn294 (2.82 Å) instead. Finally,
Asp90 of (N/S)LxxxD in TM2 forms a hydrogen
bond with Leu86 (2.94 Å) and Ser94 (2.97 Å) of TM2,
Ser132 (2.74 Å) and Ser136 (2.63 Å), and Ser295
(2.59 Å) of TM7, while the corresponding Asp83 of
opsin hydrogen bonds to the equivalent TM2
residues only (Fig. 1).
As a consequence of the template selected and the
above analysis, we believe that our MC4R model
represents a good intermediate R⁎ state, which is
appropriate for docking an agonist ligand.
Cross-linking hMC4R Cys mutants to NDP-MSH
peptide analogues
This study was carried out with 13 peptide
analogues of NDP-MSH, which contain a Cys
residue at each position of the peptide in turn and
with the hMC4R containing Cys mutations. It was
necessary to characterize the efficacy of these
cysteine mutations. The pEC50 values (log of the
ligand concentration that gave 50% of maximum
activity) of peptide agonists were determined using
ligand-dependent production of cAMP production,
as monitored using induced luciferase expression in
the presence of its substrate luciferin (see Materials
Fig. 1 (legend on next page)
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Fig. 1. (a) Three-dimensional image of the R⁎ hMC4R model. GαCT(340–350)K341L) is indicated in purple. (b) Three-
dimensional image zoomed to the area of the E/DRY motif, with interacting residues indicated. The outer helices were
removed for clarity. (c) Three-dimensional image zoomed to the area of the NPxxY motif (in yellow); Asp146 and Arg147
are indicated in blue, with interacting residues identified (see the text for further details).The images were generated using
PyMOL.54
437Melanocortin-4 Receptor/NDP-MSH Interactionsand Methods). This assay gave a pEC50 value of
8.27±0.27 (Table 1) for NDP-MSH with human
wild-type (WT) MC4R. This is comparable with the
literature values of 957, 8.3,58 and 9.259 using the
same technology for NDP-MSH with human WT
MC4R. The results demonstrated that all mutant
peptides elicited a reduction in potency, as deter-
mined by the cyclic AMP response element (CRE)-
Luciferase assay for activity with NDP-MSH com-
pared to the WT receptor (pb0.05; paired t test). The
mutant MC4Rs L106C and I125C exhibited a 10-fold
decrease in potency with NDP-MSH, whereas
D126C and H264C displayed a N1000-fold decrease
in potency, and D122C and M292C were not
stimulated at all by NDP-MSH (Table 1).Interestingly, when functional studies were per-
formed to obtain pEC50 values for the binding of the
Cys-containing peptide analogues 6, 7L, 7D, 8, and 9
to the mutant receptors, most showed little or no
activity after stimulation by the agonist NDP-MSH.
Peptide 8, however, stimulated the L106C receptor
to a greater extent than NDP-MSH such that the
pEC50 value was similar to that for the binding of
NDP-MSH to WT MC4R (see Supplementary
Material). This may suggest stabilization of a
significant interaction.
Cross-linking studies were performed between
the MC4R-containing Cys mutations and 13 pep-
tide analogues of NDP-MSH. Disulfide bond
formation was induced by incubation in the
Table 1.WTMC4R and mutant cAMP activity studies on
HEK293 CRE-Luciferase cells to determine pEC50 values













438 Melanocortin-4 Receptor/NDP-MSH Interactionspresence of copper 1,10-phenanthroline (CuP), as
described in Materials and Methods. The presence
of disulfide bonds between the receptor and the
ligand was demonstrated by detection of the biotin
attached to the peptide ligand at a position close to
the molecular mass of the MC4R on Western blot
analyses of the cross-linked samples, resolved by
SDS-PAGE.
The key residues contained within the MC4R that
were mutated to Cys include the tight acidic cluster
in TM3 (Asp122 and Asp126) and the conserved
family A residues (Leu106 and Ile125).55 Addition-
ally, important residues believed to be located in the
hydrophobic binding pocket on TM6 (His264), as
well as the residue in the MC4R (Met292) that is
equivalent to the residue involved in the binding of
retinol to bovine rhodopsin (Lys296) (Fig. 2;
Supplementary Material), were also mutated to
Cys. Each of the aforementioned mutants was
incubated with CuP in the presence of the NDP-
MSH Cys peptide containing analogues 2, 5, 6, 7L,
7D, 8, 9, and 13 (Fig. 3). The degree of covalent cross-
linking, as determined by Western blot analysis and
chemiluminescence signal, is shown in Fig. 3. The
intensity of the signal varies depending on the
occupancy of the binding site by the biotinylated
ligand. The results are discussed in detail below.
The core tetrapeptide of NDP-MSH (with both β-
turn types D-Phe7-Arg8 and His6-D-Phe7) had been
manually docked into the binding pocket of our
MC4R model using Autodock60 and refined with
MOE53 before the complete peptide was modeled in
situ with Modeller9v5,61 as described in Materials
and Methods. The modeled proximity of the
residues in the peptide to the receptor and the
experimental data were examined and compared
(see Supplementary Material). In the process, it was
found that the D-Phe7-Arg8 β-turn model for the
peptide gave a better fit to the biochemical data and
proximities. This is discussed in more detail below
(Fig. 2).
Interaction between Glu5 of NDP-MSH and MC4R
We examined the covalent interactions observed
with the Cys-substituted core peptide residues and
compared them to those predicted by our model.Peptide 5 was shown, through cross-linking, to
interact with Asp122, Ile125, and, particularly,
Asp126 (Fig. 3). Our molecular model is in agree-
ment with the side chain of Glu5 being in close
proximity to Asp126 of the receptor (Cα–Cα distance
of 5.8 Å in the model; closest distance of 2.6 Å). This
was the most intense biotin-detected band observed
by biochemical studies and predicted by computa-
tional studies. Additionally, Glu5 on the NDP-MSH
peptide lies close to Asp122 (Cα–Cα distances of
7.1 Å; closest distance of 2.5 Å) and Ile125 (Cα–Cα
distances of 8.0 Å; closest distance of 6.1 Å) of the
MC4R. Furthermore, the model predicts a novel
hydrogen bond between Ser127 (TM3) and Glu5 on
the NDP-MSH peptide.
Interactions between His6 of the tetrapeptide
and MC4R
A band with a low signal was observed, via
Western blot analysis, between peptide 6 (Cys/His
substitution) and the residues Asp122, Asp126, and
His264 on the receptor (Fig. 3). In our model, His6
interacts with D-Phe through arene–arene stacking
and with Arg8 and Trp9 through backbone interac-
tions. The cross-linking data indicated that peptide 6
interacts weakly with L106C (Cα–Cα distance of
17.6 Å; shortest distance of 16.5 Å), D122C (Cα–Cα
distance of 5.4 Å; shortest distance of 2.9 Å), I125C
(Cα–Cα distance of 5.3 Å; shortest distance of 3.9 Å),
D126C (Cα–Cα distance of 3.4 Å; shortest distance of
2.7 Å), and H264C (Cα–Cα distance of 16.8 Å;
shortest distance of 10.5 Å). However, only the
positions of residues D122C, I125C, and D126C
predicted by our model are in agreement with the
experimental data. On the other hand, it is worth
noting that Leu106, an extracellular loop residue, is
anticipated to have considerable flexibility and
could feasibly adopt an alternative conformation
closer to His6 than that predicted by our model,
thereby agreeing with the experimental finding.
Interactions between D-Phe7 of the tetrapeptide
and MC4R
The D-Phe7-to-Cys analogue showed the most
visually intense interaction with the I125C mutant
when compared to any other of the peptides and to
any of the mutant receptors (Fig. 3). It was also
shown that peptide 7D interacts with Asp122 and
His264. From our model, D-Phe7 lies in a pocket
surrounded by Phe51 of TM1, Glu100 of TM2, and
Ile125, Asp126, and Ile129 of TM3. Hogan et al.
postulated that Ile125, Ile129, and Ile291 form a
hydrophobic pocket with Ile291 on top of the DPxxY
motif, possibly acting as a rotamer switch involved
in the activation of the receptor, consistent with our
model.23 The cross-linking studies indicated that the
strongest interaction between the peptide and the
receptor involved D-Phe7 and I125C (C
α–Cα distance
of 5.1 Å; shortest distance of 3.6 Å, which is also in
agreement with our model). Additionally, the
distance from D-Phe to Asp122 (7.0 Å; shortest
Fig. 2 (legend on next page)
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Fig. 2. (a) Three-dimensional structure indicating relevant residues mentioned in this study: Leu106 (ECL1); Asp122,
Ile125, and Asp126 (TM3); Cys196 (TM5); Cys257 and His264 (TM6); and Met292 (TM7). The position of the NDP-MSH
peptide is presented in purple. A zoomed-in image of the region is presented in (b). The images were produced using
PyMOL.36 (c) A MOE two-dimensional53 depiction of the interactions involving the core of the peptide (chain B) and the
MC4R R⁎ model (chain A). The two-dimensional interaction caption is presented in (d).
440 Melanocortin-4 Receptor/NDP-MSH Interactionsdistance of 6.0 Å) predicted by our model indicated a
potential interaction, while the other interactions
analyzed were modeled with longer distances and
were not predicted to occur [e.g., Leu106 (16.2 Å;
shortest distance of 13.9 Å) and His264 (20.6 Å;
shortest distance of 17.2 Å)].
An examination of the peptide agonists (α-MSH
and NDP-MSH) by NMR suggested that L-Phe-
containing and D-Phe-containing analogues exist as
mirror images of one another.41 Lee et al. deter-
mined from NMR data that α-MSH, which has a
His-L-Phe-Arg-Trp core tetrapeptide, adopted a
hairpin–loop conformation, while NDP-MSH,
which has a His-D-Phe-Arg-Trp core, contained a
β-turn instead.19 The different orientation that
D-Phe (compared with L-Phe) would experience
inside the binding pocket may be the reason for
the greater potency and longer activity of NDP-
MSH relative to α-MSH. Additionally, it was
observed that the W258A mutation had a larger
effect on the binding affinity and potency ofα-MSH relative to NDP-MSH, suggesting that
L-Phe is positioned closer to TM6 and fits into the
hydrophobic pocket.34 However, it is important to
note that peptide 7L (L-Phe7) showed no cross-
linking to any of the MC4R mutants and, hence,
while it is likely to be positioned farther away from
TM3 towards TM6, no cross-linking was observed
with Cys at the His264 position of TM6.
Interactions between Arg8 of the tetrapeptide
and MC4R
The cross-linking study indicates that the mutant
D122C receptor interacts strongly with peptide
8 (Arg8), providing further evidence
34 that there is
an electrostatic interaction between the negatively
charged amino acid on the MC4R and the positively
charged Arg8 on the peptide agonist (Fig. 3). Not
only is Arg8 shown to interact with Asp122, but an
interaction is also formed with Asp126 (Fig. 3). This
evidence is consistent with previous findings where
Fig. 3. Interactions between peptide analogues and
key residues in the binding pocket. Membrane samples
prepared from HEK293 cells expressing the hMC4R with
Cys mutations in key positions and incubated separately
with 100 nM of each biotinylated cysteine-substituted
NDP α-MSH peptide in the absence (T, total binding) or
in the presence (NS, nonspecific binding) of 50 μM
SHU9119.
441Melanocortin-4 Receptor/NDP-MSH Interactionsexposed Cys130 is modified by (2-aminoethyl)
methanethiosulfonate, highlighting the necessity of
Asp126 on TM3 for ligand binding.62 Our model
suggests that Arg8 of NDP-MSH can form a direct
contact with Asp126 (Cα–Cα distance of 6.52 Å;
shortest distance of 5.2 Å). Furthermore, our model
suggests that the side chain of Arg8 forms a
hydrogen bondwith Asp122 of TM3 and a backbone
interaction with Tyr287 of TM7. Although Tyr287
was not tested experimentally, Hogan et al. also
postulated that Tyr287 was located in the MC4R
binding site and was likely to have direct contacts
with MC4R agonists.23
Interactions between Trp9 of the tetrapeptide
and MC4R
Our cross-linking studies have shown that Trp9was
in close proximity to TM6 and TM7 (residues His264
and Met292, respectively) and also suggested an
interaction between Trp9 and Ile125. The modeling
work suggested that the Trp9 residue lies in a pocket
with D-Phe, Asp126, Ile129, Cys130, and Leu133 of
TM3, and with Phe261 of TM6. Reasonably strong
interactions of the peptidewere observedwithH264C
(His264 Cα–Cα distance of 11.7 Å; shortest distance of
7.7 Å) and M292C (M292 Cα–Cα distance of 12.6 Å;
closest contact of 6.5 Å). In the cross-linking study,
however, no direct interactions are predicted in the
model, and some structural flexibility should be
incorporated as the receptor accommodates binding
of the ligand. Previous modeling studies also sug-
gested that the side chain of Trp9 may interact with
TM6 in a similar region as L-Phe7.
13
Identification of peptide contacts between the
Cys-containing peptide analogues and WT
MC4R
Experiments were performed to cross-link the
NDP-MSH Cys analogues to the WT receptor.
Figure 4 illustrates the cross-linking of peptide
analogues to the native receptor when Cys is
present near the amino-terminus of the peptide
(particularly at position 2) or near the carboxyl-
terminus of the peptide (positions 12 and 13).
These data suggested that one or more Cys
residues in the WT receptor (there are 15 Cys
residues in MC4R) make a direct contact with
residues close to the amino-terminus and carboxyl-
terminus of the agonist NDP-MSH. The Kd values
for cysteine substitutions at positions 1, 2, 10, and
11 were not significantly different from the native
peptide (Student's t test, pN0.05; data not shown).
In contrast, binding affinity was not readily
detectable with cysteine substitutions at positions
His-Phe-Arg-Trp (unpublished data).
Mapping the N-terminus/C-terminus interactions
of NDP-MSH and MC4R
A selection of the 15 Cys residues in the MC4R
were individually mutated to Ala. These residueswere chosen based originally on a bovine-rhodop-
sin-derived MC4R model.62 Seven of these MC4R
residues (C40, C130, C177, C196, C257, C271, and
C277) occupied positions that are likely to be
accessible to the ligand. Peptides 2 and 13 were
cross-linked to each Cys-to-Ala mutant receptor to
identify the contact site for the N-terminus and the
C-terminus of NDP-MSH. Functional characteriza-
tion of these mutants is presented by Cox et al.62
Cross-linking was not observed between the
mutant receptor C196A and peptide 2 (Fig. 5),
implying that Cys196 contained within the recep-
tor is located in close proximity to residue Tyr2 on
NDP-MSH. Residue Cys196 is predicted to be
located at the extracellular end of TM5 and is
orientated into the binding pocket. Previous data
have suggested that substitution at positions Ser1,
Tyr2, and Ser3 in NDP-MSH, with less hydrophilic
residues, slightly reduces affinity and potency.63,64
By docking the D-Phe7-Arg8 β-turn form of the
peptide into our MC4R model, we observed
interactions between ECL2 and TM5, consistent
with the biochemical data. From our model, Ser1 of
the peptide ligand is predicted to form hydrogen
bonds with Val179 on TM4 of the receptor. Our
MC4R model also predicted another polar residue
located on TM5 (Ser188) to be involved in
hydrogen bonding to the N-terminus of the
peptide. Although the C196A mutation of the
MC4R showed little effect on ligand binding,62
when the MC4R was mutated to D189A (ECL2), a
dramatic decrease in both affinity for the agonist
NDP-MSH (no binding detected) and potency of
the agonist NDP-MSH (from pEC50=8.27±0.27 to
pEC50=5.15±0.12; WT versus D189A; over 1000-
fold) was observed (Fig. 6). Interestingly, with the
truncated cyclic peptide agonist analogue MTII,
efficacy did not appear to be affected to the same
extent (from pEC50=7.78±0.13 to pEC50=7.33±
0.18; under 3-fold).
Fig. 4. Detection of WT MC4R cross-linked with the cysteine-substituted peptide analogues. Membrane samples
prepared fromHEK293 cells expressing the hMC4R were incubated separately with 100 nM of each biotinylated cysteine-
substituted NDP α-MSH peptide in the absence (T, total binding) or in the presence (NS, nonspecific binding) of 50 μM
SHU9119. Peptide 1 has cysteine at position 1 of the ligand; peptide 2 has cysteine at position 2, and so forth. Peptide 7L
has L-cysteine at position 7, whereas peptide 7D has D-Cys at the position. Cys-to-Cys cross-linking was induced by
further incubation in the presence of CuP. Samples were then analyzed by SDS-PAGE, followed by Western blot analysis
and detection of biotin using streptavidin polyperoxidase and chemiluminescence.
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is close to the extracellular end of TM6 and TM7, and
ECL3 (Fig. 7). Western blot analysis of peptide 13
demonstrates cross-linking of the peptide to all of
the mutant receptors, except for C257A-MC4R,
implying that the carboxyl-terminus interacts with
TM6 (Fig. 3). The Cys(6.47) residue is located on
TM6 of the MC4R (Cys257) just below the hydro-
phobic pocket (Trp257, Phe261, Tyr268, and Ile269).
It is conceivable that due to TM6 flexibility, Cys257
in the MC4R may be more accessible in the active
state of the receptor.Fig. 6. Effect of the D189A mutation of the MC4R on
MTII and NDP-MSH agonist stimulation. Activity studiesDiscussion
The aim of this work was to better map the
amino acid residues surrounding the binding
pocket of the MC4R for one of its agonists, NDP-
MSH, using a covalent attachment approach,
coupled with a more accurate modeling of the
receptor in its activated state. In order to identify
specific interactions between the MC4R and NDP-
MSH, we cross-linked cysteine-containing peptide
analogues to the endogenous and mutated Cys
residues on the receptor. The peptide ligands were
labeled with biotin at their N-terminus and cross-
linked to the receptor, and the complex was
detected using streptavidin polyperoxidase.
In this study, we have demonstrated direct
interactions between Cys-containing ligand homo-Fig. 5. Detection of residue on the MC4R that interacts
with the N-terminus of the agonist. Membrane samples
prepared from HEK293 cells expressing the MC4R were
incubated separately with 100 nM of each biotinylated
cysteine-substituted NDP-MSH peptide 2 (T, total bind-
ing). The WT receptor (lane 1) was also incubated in the
presence of 50 μM SHU9119 (NS, nonspecific binding) and
1 mM GTPγS. Peptide 2 has cysteine at position 2 of the
NDP-MSH ligand. Samples were then analyzed by SDS-
PAGE, followed by Western blot analysis and detection of
biotin using streptavidin polyperoxidase and chemilumi-
nescence. The absence of cross-linking is an indication of
the position of interaction of peptide 2 and is located at
C196 (lane 6).logues and both the WT receptor and versions
containing substituted cysteines, which resulted in
receptors to which the peptide ligandwas covalently
attached. The results revealed the proximity of
residues at positions 5–9 of NDP-MSH to residues
Leu106, Asp122, Ile125, Asp126, His264, andMet292
of the MC4R. Each position on the core peptide was
shown to interact to varying degrees with at least
two of the aforementioned residues on TM3, TM6,
and TM7. However, a certain amount of caution
should be exercised when analyzing the cross-
linking data. There is the possibility of interpreting
interactions that are not “real” based on a low level ofof the MC4R were performed in HEK293 cells stably
expressing CRE-Luciferase and with transient transfection
of the MC4R. Activity is expressed as a percentage of the
luminescence response compared to 10 mM forskolin (a
direct adenylate cyclase stimulator). The development of
the CRE-Luciferase assay was described by Stables et al.78
Twenty-four hours posttransfection, HEK293 CRE-Lucif-
erase cells were plated and cultured for a further 12–18 h.
The medium was replaced, and the appropriate concen-
tration of the agonist NDP-MSH was added. After
incubation, Luclite® reagent (Perkin-Elmer) containing
the substrate for the luciferase was added to each well.
Luciferase activity was determined by scintillation count-
ing. The data are representative of at least three
independent experiments performed in triplicate and
analyzed in triplicate by one-site competition plots using
GraphPad PRISM 3.02 software. NDP-MSH pEC50 values
were shifted from 8.27±0.27 to 5.15±0.12 (over 1000-fold)
when D189 was mutated to Ala, respectively; however,
only a small shift from 7.78±0.13 to 7.33±0.18 (less than
3-fold) was seen for the truncated agonist MTII.
Fig. 7. Detection of residue on the MC4R that interacts
with the C-terminus of the agonist. Membrane samples
prepared from HEK293 cells expressing the MC4R were
incubated separately with 100 nM of each biotinylated
cysteine-substituted NDP-MSH peptide 13 in the absence
(T, total binding) or in the presence (N, nonspecific
binding) of 50 μM SHU9119 and 1 mMGTPγS. Peptide 13
has cysteine at position 13 of the NDP-MSH ligand.
Cysteine-to-cysteine cross-linking was induced by further
incubation in the presence of CuP. Samples were then
analyzed by SDS-PAGE, followed by Western blot
analysis and detection of biotin using streptavidin poly-
peroxidase and chemiluminescence. The absence of cross-
linking is an indication of the position of interaction of
peptide 13. Molecular mass is expressed in kilodaltons.
The MC4R/peptide complex is located at 37 kDa.
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serendipitous interactions (e.g., as the peptide enters
the binding cleft) or flexibility (as the receptor and
ligand “accommodate” the interaction). Further-
more, when charged residues either on the ligand
or on the peptide are substituted with cysteines,
important electrostatic interactions between the
ligand and the receptor may be affected.
To aid the interpretation of these binding data, we
constructed a theoretical model whereby the core
tetrapeptide was docked initially, followed in a
sequential manner by the N-terminus and the C-
terminus of the peptide, akin to the proposed
binding mode of adrenaline to the β2-adrenergic
receptor.65 A number of research groups have
developed R⁎-state models for the MC4R, including
Schiöth et al., who utilized an MC4R molecular
model to suggest that a 76° counterclockwise turn
of TM3 may be important for MC4R activation.41
Pogozheva et al.33 employed two different structur-
al templates, namely, a model of the inactive
conformation of the hMC4R29 and a model of the
active conformation of the μ-opioid receptor. They
then used distance constraints from the inactive
conformation of rhodopsin, together with experi-
mental constraints compatible with active states in
several GPCRs, to develop an R⁎ model of the
MC4R into which they positioned NDP-MSH into
the binding pocket using distance geometry calcu-
lations. Cho et al.20 used Autodock66 to position an
NMR structure of NDP-MSH in the binding pocket
of their MC4R model, followed by refinement with
a short molecular dynamics simulation. They
determined that NDP-MSH formed a β-turn con-
formation around the D-Phe7-Arg8 sequence, with
the hydrophobic side chain of the D-Phe7 residue
located away from the negatively charged side
chains of the acidic residues. In their model, the
Arg8 residue is involved in charge–charge interac-
tions with the acidic residues. Finally, Hogan et al.23
used the observation that a switch in the orientation
of Trp258 (from perpendicular to the plane of themembrane to parallel with the plane of the
membrane)49 and a change in the conformation of
the aromatic cluster of residues in TM6 are both
involved in receptor activation.67 In developing
their MC4R R⁎model, Hogan et al. first changed the
conformation of Phe254, Trp258, and Phe262 in
their bovine-rhodopsin-based MC4R model, and
then reduced the kink induced by Pro260 in TM6
from an initial 30° to a final lower kink of 11°.23
Here, we utilized the recently elucidated crystal
structures to generate R⁎-state models of the MC4R,
from which the structure of a complex with NDP-
MSH was developed in a ligand-based modeling
approach. This approach allowed us to examine the
proposed interactions and the roles of the various
mutations studied here and reported earlier in the
literature. Previous NMR studies on isolated NDP-
MSH have resolved two different structures for the
peptide ligand. Cho et al. indicated that the central
residues forming the turn conformation in NDP-
MSH are the His6-D-Phe7 pair.
20 In contrast, Hogan
et al. later studied cyclic decapeptides with the
consensus tetrapeptide sequence His-D-Phe7-Arg8-
Trp locked in a type II′ β-turn.23 With the use of our
MC4R R⁎-state model based on the opsin template,
the D-Phe7-Arg8 turn structure fitted the biochemical
data best. On the other hand, some of the biochem-
ical data did fit both models; however, it may be that
different conformational forms of the ligand interact
preferentially with different conformational states of
the receptor. Our model is, however, limited by
focusing on the predicted active state based on the
active state of opsin.51
It appears that agonist binding may occur in at
least two stages. Firstly, the core tetrapeptide is
predicted to neutralize the negative repulsion
between TM2 and TM3. The documented interac-
tion between Arg8 on the peptide and Asp122 on
the receptor34 was in agreement with our data,
which also indicated that Asp126 is within
interaction distance.62 In this study, as supported
by both cross-linking studies and modeling anal-
ysis, both Glu5 and His6 are shown to be in close
proximity to TM3, including the residues Asp122,
Asp126, and Ile125 (see Supplementary Material).
His6 in the core tetrapeptide is not predicted to
form direct interactions with the acidic bundle on
TM3 of the MC4R, but maintains the “bioactive”
conformation of the peptide ligand.32,68–70 Some
data, however, have implicated residues Asp122,
Asp126, His264, and Phe21832,34 in forming direct
interactions with His6 (Supplementary Material).
Here, our cross-linking studies and model suggest
that His6 lies in close proximity to Asp122 and
Asp126, but does not interact with the receptor.
Rather, His6 forms interactions with residues of the
peptide ligand itself, including D-Phe7, Arg8, and
Trp9, thus supporting the theory of the importance
of His6 in stabilizing the structure of the peptide
ligand.22,32,68–70
Previous data have highlighted the importance of
burying the hydrophobic residues (D-Phe7 and Trp9)
in the hydrophobic cleft on TM6. Interestingly, one
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between Ile125 (TM3) and D-Phe7 on the peptide.
This interaction was pivotal in our decision to use
the D-Phe7-Arg8 β-turn of NDP-MSH over the His6-
D-Phe7 turn for the selection of our model complex.
Interactions between TM3 and D-Phe7 have only
recently been suggested,23 implicating a third
interaction in addition to the ionic TM3 interaction
and TM6 hydrophobic binding pocket. The ionic
interactions may allow rotation of TM3 towards
TM2, which unlocks the putative activation motif
DRY. Interestingly, one might expect the positively
charged residue at position 8 (Arg8) to be respon-
sible for activation. However, Arg8 has been
implicated mainly in potency and affinity, while
the peptide ligand position 7 (Phe/Nal7) is mainly
responsible for agonist/antagonist characteristics.71
For example, nonpeptide agonists for the MC4R
have been developed excluding any involvement of
the Arg8 moiety.
22 Furthermore, D-Phe7 has been
shown to increase the potency of the ligand; some
even argue that it interacts more strongly with the
receptor than with L-Phe.7 In the antagonist, D-Nal
may exert steric hindrance, preventing the move-
ment of TM3. The lack of interaction between the
L-Phe7 peptide analogue and any of the key
predicted residues of the receptor may be of some
significance, and it may suggest that there is an
alternative binding cavity sampled by L-Phe that has
not been exploited in our cross-linking study (e.g.,
with Phe284 and Tyr287 of TM6).
Experimentally, Trp9 on the peptide ligand was
shown to be in close proximity to both TM6 and
TM7, but the modeling data also indicated that
residues on TM3, including Asp126, Ile129, Cys130,
and Leu133, lie in the proximity of this residue.
However, the predicted proximity of Cys130 to Trp9
at 5.2 Å in the model is not supported by the cross-
linking studies. Perhaps the environment is not
conducive to oxidation or the residues are not
appropriately positioned.
In contrast, Met292 of TM7 was newly identified
to interact with Trp9. This interaction is interesting,
as the equivalent residue in bovine rhodopsin
Lys296 is involved in covalently attaching the
chromophore to the receptor. For the first time,
this residue has been shown to be located in the
NDP-MSH pocket, as demonstrated by cross-linking
(Fig. 3) and functional studies (Table 1). In this
study, NDP-MSH exhibited the characteristics of the
binding of an antagonist to the mutant M292C-
MC4R. Furthermore, previous studies demonstrated
that M292C-MC4R exerted a dominant-negative
effect on activation when in complex with another
form of the receptor (unpublished data). Also, a
cysteine at the equivalent position in the neurokinin
NK2 receptor was shown to be cross-linked to the C-
terminal residues of that ligand.72 All these reinforce
the significance of this residue in the ligand binding
cavity of many GPCRs.
The residues His6, Arg8, and Trp9 on the peptide
ligand all showed a level of interaction with TM6
at residue His264. This residue in our model doesnot appear to be directly involved in the active
binding pocket, but previous data have implicated
it as important for ligand binding.33,34,40,73 Nickolls
et al. calculated a nonsignificant change in affinity
for the peptide agonist NDP-MSH with H264A-
MC4R.37 Here, we show that activity is dramati-
cally reduced when His264 is mutated to Cys. This
evidence points toward His264 being involved in
the active-state structure of the MC4R. Leu106 is
also not predicted to be directly involved in the
agonist binding pocket, but cross-linking has
shown interactions with residues His6 and D-Phe7
on the peptide. This residue is located at the top of
TM2 on ECL1 in the model and is predicted to
interact with the backbone of nearby Ile102 and
Leu107. The side chain is exposed to the solvent,
however, and, given its loop position, is likely to
be flexible and thus could adopt alternative
conformations. The residue at this position in the
melanocortin-1 receptor (MC1R), when mutated,
caused constitutive activity.36 This mutation L106C
may alter the proposed ionic arrangement between
TM2 and TM3, as suggested from studies of the
homologous residue in MC1R, thereby resulting in
constitutive activity.36 A large body of evidence
suggests that Arg8 is involved in stabilizing the
equilibrium between Asp122 (TM3) and Glu100
(TM2).43 Thus, if the equilibrium is altered by the
mutation L106C, the function of Arg8 becomes
redundant. This finding is supported by our
binding data (Fig. 3) where peptide 8, which
contains the replacement of Arg8 with Cys8 when
bound to L106C-MC4R, behaves similarly to the
interaction of NDP-MSH with WT MC4R.
After the core tetrapeptide of NDP-MSH had
been docked, its N-terminal and C-terminal
regions were mapped into the model, and a series
of potential hydrogen bonds between TM4, ECL2,
and TM5 was apparent, consistent with the
biochemical data. Previous data have suggested
that substitution at positions Ser1, Tyr2, and Ser3 of
NDP-MSH, with less hydrophilic residues, slightly
reduces affinity and potency.63,64 From our model,
Ser1 of the peptide ligand is predicted to form a
hydrogen bond with Val179 on TM4 of the
receptor; thus, a hydrophobic residue at this
peptide position can be expected to reduce affinity.
Our data and model also validate a novel
interaction between Cys196 (TM5) and Asp189
(ECL2) with the N-terminal region of the peptide
(see Supplementary Material). Investigation into
the region on the MC4R (TM5) where the amino-
terminus of the peptide agonist docks raised the
possibility of a hydrogen-bond interaction between
Ser188 on the receptor and Ser3 on the peptide. It
is perhaps relevant that mutation of Asp189 to Ala
dramatically decreased both the affinity and the
potency of NDP-MSH.
It is important to note that all attempts to mutate
or extend ECL2 destroyed the functionality of the
MC4R (Cox et al., unpublished data). The modeling
work suggests that the small ECL2 forms important
interactions with the peptide ligand and is clearly
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MTII, which lacks the N-terminal Ser1-Tyr2-Ser3
motif of NDP-MSH activity, is not affected in the
D189A mutant. Therefore, the hydrophilic nature of
TM4 and TM5 may be important in forming a
binding pocket for the amino-terminus of the
peptide ligand. Although the N-terminal region of
the peptide, when absent, is not required, it may
exert an effect on the conformation of the “bioac-
tive” sequence when present. The residue Cys196
(5.42) in TM5 of the MC4R is equivalent to Ser204
(5.42) in TM5 of the β2-adrenergic receptor. This
residue is one of a cluster of Ser residues at the TM5/
ECL2 interface that are mainly involved in hydrogen
bonding to the catecholamine agonist.74 These data
begin to shed light on the critical nature of ECL2 in
WT MC4R.
For the first time, direct interactions of the
carboxyl-terminus of NDP-MSH with the MC4R
were observed. The residue at position Val13 was
shown to be in close proximity to Cys257(6.47)
located on TM6. Cys257(6.47) is at an interesting
position, as the equivalent residue in the β2-
adrenergic receptor is accessible, but only in the
active conformation.55 Furthermore, recent studies
that engineered metal ion binding sites in the β2-
adrenergic receptor demonstrated that this region
moves towards TM3, in particular towards Asp
(2.29), upon activation by an agonist.75 It is
suggested that this mechanism of action is common
to all GPCRs.76 The amino-terminus and carboxyl-
terminus of the NDP-MSH ligand have previously
been implicated in potency.28 The docking of the
carboxyl-terminus produced here provides tentative
support for the suggestion that the MC4R is
activated by sequential interactions of the agonist
with the receptor.65 Subsequent interactions may
include possible hydrogen bonds between TM5 and
the amino-terminus of the peptide. Once the
receptor is activated, the N-terminal and C-terminal
regions of the peptide are able to dock at the TM4/
TM5 and TM6/TM7 interfaces, respectively, poten-
tiating the signal. If the peptide ligand docks by aTable 2. Cys-containing peptide analogues of NDP-MSH
NDP-MSH is made up of 13 amino acids. A Cys residue is replaced
amino-terminus.series of steps, each exposing more and more
interfaces, this would complement experiments
performed on the β2-adrenergic receptor that led




The expression vector pcDNA3 containing cDNA for
the hMC4R was provided by Dr. Sharon C. Chetham
(BASF Pharma, Nottingham, UK). [125I]NDP-MSH was
obtained from Perkin-Elmer Life Sciences (Boston, MA,
USA). Nonradioactive peptides were purchased from
Bachem (St. Helens, UK), cell culture reagents were
obtained from Invitrogen (Paisley, UK), and protease
inhibitor cocktail tablets were obtained from Roche
(Lewes, UK). Oligonucleotide primers were synthesized
by Sigma-Genosys Ltd. (Pamisford, UK).
Cysteine-containing peptides
Peptide analogues of NDP-MSH were designed with
L-Cys residues substituted into each position and with
biotin attached to the amino-terminus. In total, 14 peptides
were synthesized, as both the L-Phe form and the D-Phe
form of the ligand (α-MSH and NDP-MSH, respectively)
are able to interact with the MC4Rwith nanomolar affinity
(Table 2). The peptides were designed, synthesized,
purified, and donated by BASF Pharma.
Mutagenesis
Point mutations were introduced into the MC4R
sequence using the QuikChange® Site-Directed Mutagen-
esis Kit (Stratagene), with pcDNA3-MC4R vector as
template.
Cell growth
HEK293 cells were routinely maintained in Dulbecco's
modified Eagle's medium supplemented with 10% fetalin turn for each position in NDP-MSH. Biotin was attached to the
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and GlutaMAX™ (Invitrogen). Stably transfected cells
were grown in the same medium supplemented with
800 μg/ml geneticin G418 sulfate. Cells were grown at
37 °C in 5% CO2.
Cross-linking the peptide to the receptor
Membranes were diluted to a concentration of 25 μg/ml
with binding buffer [25 mM Hepes–KOH, 1.5 mM CaCl2,
1 mM MgSO4, 100 mM NaCl, and 1 mM GTPγS (pH 7.0)
plus the protease inhibitors]. Each peptide (concentrations
are experiment dependent) was added to the membranes
and allowed to equilibrate for 45 min. At 22 °C for 1 h,
cross-linking was induced by addition of 5 mM CuP. The
reaction was stopped by addition of 5× SDS sample buffer
[60 mM Tris–HCl (pH 6.8), 2% SDS, and 10% glycerol]
containing 25 mM N-ethyl maleimide to react with any
free sulfhydryl groups. Nonspecific binding was deter-
mined by addition of excess SHU9119.
CRE-Luciferase assay
The development of the CRE-Luciferase assay was
described by Stables et al.77 and has previously been
utilized in our laboratory.78 Twenty-four hours posttrans-
fection, HEK293 CRE-Luciferase cells were plated onto
96-well black-wall, clear-bottom, poly-D-lysine-coated
microplates (Corning Costar) at a density of
50,000 cells/well and cultured for a further 12–18 h.
Medium was replaced with 100 ml of Phenol-red-free
culture medium, including IBMX and the appropriate
concentration of the agonist NDP-MSH. Microtiter plates
were incubated for 4 h at 37 °C, after which Luclite®
reagent (Perkin-Elmer) was added to each well. The
plates were sealed and subjected to dark adaptation for
5 min at room temperature. Luciferase activity was
determined by scintillation counting using a TOPCount
scintillation counter (Perkin-Elmer).
Data analysis
All measurements, except where stated, were carried
out in triplicate in three independent experiments. The
values quoted and depicted graphically are the means of
independent determinations with the standard error of the
mean. In competition binding studies, counts were
normalized to the maximal specific binding within each
data set, and IC50 values were calculated with a single site-
binding model fitted with the aid of GraphPad PRISM 3.0
software (San Diego, CA). Kd values were obtained from
the IC50 using the following equation: Kd = IC50−
[radioligand].79 In a similar fashion, EC50 values were
calculated from the fit of sigmoidal concentration–
response curves (three-parameter fit). pIC50 refers to
− log IC50, and pEC50 refers to − log EC50. The significance
of differences between values was determined by a
comparison of the mean values using two-tailed unpaired
or paired Student's t test.
Comparative modeling of MC4R: Sequence alignment
Recently, crystal structures of the active GPCR opsin in
an R⁎ state (PDB code 3CAP; 2.9 Å)50 and of a complex
derived from the C-terminus of the Gα subunit of
transducin (PDB code 3DQB; 3.2 Å),51 which have
previously been used for modeling the active state hβ2R,were published.80 The global sequence identity between the
MC4R and opsin is only ∼16%, which is generally
considered not to be sufficient for reliable homology
modeling.81,82 However, when the TM regions are consid-
ered, the identity increases: TM1, 13.3% (43.3%); TM2,
26.7% (60%); TM3, 18.2% (42.4%); TM4, 4.3% (34.8%); TM5,
25% (50%); TM6, 16.1% (58.1%); TM7, 14.3% (52.4%).83
A multiple-sequence alignment was made between the
amino acid sequence of the opsin and theMC4R (SwissProt
accession code P32245) using CLUSTALW84 and subjected
to manual inspection to confirm that the conserved residues
amongmost GPCRs85 were aligned (496 class A sequences).
The alignment was in agreement with that published by
Yang et al.83 However, α-aneurysms (the insertion of an
extra residue in a turn) are present in TM2 and TM5 of
rhodopsin, but may be absent in other GPCRs, with such a
misalignment in the area around such insertions being
potentially detrimental to modeling. Chai et al.29 utilized an
alternative alignment for TM2 of the MC4R with a gap
being aligned to Gly89 of rhodopsin, resulting in the
conserved Glu100 in TM2, which, being oriented into the
binding pocket, has been thought to be important for ligand
binding.34 A similar orientation of Glu100 is also proposed
by Haskell-Luevano et al.35 In contrast, Chai et al.
determined that Met200 (hMC4R) in TM5 was orientated
into the pocket when the rhodopsin α-aneurysm was
preserved.29 In this work, an additional set of models was
generated using the alignment of Chai et al.29MC4R disulfide bonds
The melanocortin family is interesting as it lacks the
family A disulfide bond between TM3 and ECL2. Instead,
there is a putative disulfide bond in ECL3 between Cys267
and Cys275 in the MC1R.86 In the MC4R, there may be a
similar bond between Cys277 and Cys279; in the absence of
one of these Cys residues, the other is induced to form a
deleterious disulfide bondwith Cys271.87 In contrast, in our
hands (Dr A. Cox, unpublished data), similar mutants do
not show the same effect. It is possible that previous
studies87 reflect more the nature of the substituted residue
than disulfide bond formation: Cys-to-Ala mutations in our
case versus Cys-to-Arg mutations in Tarnow et al.87 This is
reinforced by our SDS-PAGE analysis in the absence of
β-mercaptoethanol, where no change in migration was
observed. Subsequently, no disulfide bonds were enforced
in the modeling work.Models of the R⁎-state MC4R
With the above alignments and individual and template
combinations, we used Modeller9v561 to generate differ-
ent models of the MC4R. The Modeller software imple-
mented comparative protein structure modeling by
satisfying spatial restraints.61 The alignment is used to
construct a set of geometrical criteria that are converted
into probability density functions (PDFs) for each
restraint. The PDFs include the following:
(1) homology-derived restraints on distances and
dihedral angles in the target sequence, taken from its
alignment with the template structure(s)
(2) stereochemical restraints such as bond length and
bond angle preferences, obtained from the CHARMM-
22 molecular mechanics force field
(3) statistical preferences for dihedral angles and
nonbonded interatomic distances, obtained from a
representative set of known protein structures.88
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tances, and main-chain–side-chain dihedral angles. The
three-dimensional model of a protein is obtained by
optimization of molecular PDFs such that the model
violates the input restraints as little as possible. Four
hundred models of the backbone of the target complex
were developed, and a global optimization procedure
refines the positions of all heavy atoms in the protein. A
subsequent simulated annealing refinement protocol was
applied to the loop regions.89 The best model was selected
using a combination of the Modeller objective score and a
selection of protein assessment tools. PROCHECK90 was
employed to perform a stereochemical check, with every
amino acid being classified as having a favored, addition-
ally allowed, generously allowed, or disallowed confor-
mation. ERRAT52 counts the number of nonbonded
interactions between atoms (CC, CN, CO, NN, NO, and
OO) within a cutoff distance of 3.5 Å and yields an overall
quality factor for each structure, which is expressed as the
percentage of protein for which the calculated error value
falls below a 95% rejection limit. Normally accepted model
structures produce values above 50, with a higher score
indicating that the model has a better ratio of nonbonded
interactions. The final model selected yielded the overall
best performance across the validation tools, coupled with
a structural analysis of the binding pocket.
Models of the MC4R/peptide β-turn
D-Phe7-Arg8-Trp9 was previously determined as the
minimal NDP-MSH fragment that possesses full agonist
efficacy.34 The triplet peptide RFF, the key motif of the
natural antagonist AGRP, was extracted from the NMR
structure (PDB code 1HYK) and used to model the core
peptide of NDP-MSH, Glu5-His6-D-Phe7-Arg8-Trp9, as a β-
turn. Although earlier work suggested that the center of
the message sequence (D-Phe7-Arg8) of NDP-MSH would
form a stable turn structure, the NMRwork of Cho et al. on
NDP-MSH indicated that the central residues forming the
turn conformation are the His6-D-Phe7 pair.
20 In contrast,
Hogan et al. examined cyclic decapeptides with the
consensus tetrapeptide sequence His-D-Phe-Arg-Trp
locked in a type II′ β-turn and produced an NMR model
with the turn at D-Phe7-Arg8.
23 Given this uncertainty,
peptide models with the β-turn at His6-D-Phe7 and D-Phe7-
Arg8 were used in the subsequent studies.
The core peptide was manually docked into the pocket
of the MC4R in such a way that Arg8 was positioned
within interacting distance of a negatively charged pocket
consisting of Asp122 and Asp126 of TM3, with Trp9
positioned closer to TM6. These “R⁎ models” served as
starting structures in an automated docking procedure
using Autodock,91 allowing for peptide side-chain flexi-
bility. Partial charges on the protein and peptide were
determined using Kollman charges. A cubic grid of
70 Å×70 Å×68 Å around the active site was constructed
using the Autogrid program, with a grid point step of
0.375 Å. A Lamarckian genetic algorithm, coupled with
local search, was used for docking, with the default
parameters implemented in Autodock4. The number of
docking runs was set to 175, while ga_num_evals was set
to 2,500,000 and ga_num_generations was set to 27,000.
To generate input files, we used the AutoDockTools
program†. The conformations showing a lower free
energy of binding for each ligand were further analyzed.†http://www.scripps.edu/pub/olson-web/doc/autodock/
tools.htmlModels of the MC4R/NDP-MSH complex
To further refine the complex structure, we modeled
the full peptide structure complexed with the MC4R
model using Modeller9v5 after adapting the CHARMM
topology files in Modeller9v5 to accurately structure
Nle and D-Phe. In this way, we modeled conformational
changes induced by the core peptide first determined as
the minimal NDP-MSH fragment that possesses full
agonist efficacy at the MC4R,34 followed by the fitting
of N-terminal and C-terminal regions. The Protonate3D
module in MOE53 was used to assign optimal free-
energy proton geometry and ionization states to the
model using a generalized Born electrostatics model.
The coordinates of the final model are available upon
request.
Hydrogen-bond analysis
Hydrogen bondswere enumerated inMOE53 and scored
by a pairwise comparison of heavy atoms, which includes
parameters such as atom types (element, hybridization,
and bonding environment), distance, and in-plane and
out-of-plane angles of substituents. Having been trained
on large quantities of protein data using contact statistics,
for some atom pair combinations (e.g., secondary amine
nitrogen and carbonyl oxygen) the MOE software consid-
ered a hydrogen bond was considered possible and a
scoring functionwas defined.92 Receptor residues and ions
are included in the two-dimensional interaction plots if
they are sufficiently close to the ligand (having defined a
maximum distance of 4.5 Å between heavy atoms of the
ligand and the receptor ). The distance was then extended
to 4.6 Å, within which range a residue must have two
atoms, and so on, out to 10 atoms at 5.4 Å.Acknowledgements
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